This paper was based on 122 patients with 163 imagings with 99mTc-Tektrotyd® SPECT/CT from 12/10/2012 to 17/12/2015. All the data were collected retrospectively. General data show: constant increasing number of patients; patients on imaging were 55% women and 45% men; majority of patients older than 50 (91% of patients are 50 or older); average age of patients on imaging is 62,3. There are also data that are medical in the strict sense. Oncologists sent 60% of the patients. Histopathological diagnosis of NET was found in 21 patient, noting that the data were not available for all the patients. In 21% of patients PET/CT was performed, noting that this information was recorded only if the patient brought a copy of a PET/CT finding to the doctor, and it was archived. Elapsed time between PET/CT and SPECT/CT was 120 days, and the median was 65,5 days. Lesions with accumulation were concordant in PET/CT and SPECT/CT imaging comprised 43% of the cases with solitary lesions, and 48% of the multiple lesions. By PET/CT imaging more positive lesions were registered than by SPECT/CT. In the group of patients with multiple lesions there were 31% of accumulating lesions that were visible in PET/CT, but not in SPECT/CT. Sensitivity of SPECT with s 99mTc-Tektrotyd® was 71%. According to the accumulations in SPECT/CT there were 30% of patients with advanced disease, of which 36% had PET/CT. Most frequent tests recommended were MR and/or CT and PET/CT. Results show that 41% of patients had chromogranin A levels determined. There were 39 patients with elevated chromogranin A levels, of which 38% had a pathologic accumulation visible on SPECT/CT.